key: cord-0310288-sh1nrl5n
authors: Coleman, M. J.; Espino, L. M.; Lebensohn, H.; Zimkute, M. V.; Yaghooti, N.; Ling, C. L.; Gross, J. M.; Listwan, N.; Cano, S.; Garcia, V.; Lovato, D. M.; Tigert, S. L.; Jones, D.; Gullapalli, R. R.; Rakov, N. E.; Torrazza Perez, E. G.; Castillo, E. F.
title: Individuals with Metabolic Syndrome show altered fecal lipidomic profiles with no signs of intestinal inflammation or increased intestinal permeability: a pilot study
date: 2022-02-26
journal: nan
DOI: 10.1101/2022.02.24.22271487
sha: 506d24bdff495f54760fe7895c6fa1db6bcace10
doc_id: 310288
cord_uid: sh1nrl5n

Metabolic Syndrome (MetS) is a clinical diagnosis where patients exhibit three out of the five risk factors: hypertriglyceridemia, low HDL cholesterol, hyperglycemia, hypertension or increased abdominal obesity. MetS arises due to dysregulated metabolic pathways that culminate with insulin resistance and put individuals at risk to develop various comorbidities with far-reaching medical consequences such as non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease. As it stands, the exact pathogenesis of MetS as well as the involvement of the gastrointestinal tract in MetS is not fully understood. Our study aimed to evaluate intestinal health in human subjects with MetS with the goal to evaluate for any signs of underlying gut inflammation, increased intestinal permeability, and alterations in host-microbiota metabolism as assessed by fecal metabolites. No signs of intestinal inflammation or increased intestinal permeability were observed in MetS group compared to our control group. However, we found a significant increase in 417 lipid features of the gut lipidome in our MetS cohort. An identified fecal lipid, diacyl-glycerophosphocholine, showed a strong correlation with several MetS risk factors. An although our MetS cohort showed no signs of intestinal inflammation they presented with increased levels of serum TNF that also correlated with increasing triglyceride and fecal diacyl-glycerophosphocholine levels, and decreasing HDL cholesterol levels. Taken together, our main results show MetS subjects show major alterations in fecal lipid profiles suggesting alterations in intestinal host-microbiota metabolism that may arise before concrete signs of gut inflammation or intestinal permeability become apparent. Lastly, we posit fecal metabolomics could serve as a non-invasive, accurate screening method for both MetS and NAFLD.

The global incidence of Metabolic Syndrome (MetS), affecting over 25% of the global population (~1.97 billion) and 33% of those living in the United States, has severe health and economic consequences (1) (2) (3) . MetS is comprised of multiple dysregulated metabolic pathways that can cause or result in insulin resistance (4) . Current diagnostic criteria for MetS must include three out of the five risk factors: hypertriglyceridemia, low HDL cholesterol, hyperglycemia, hypertension (HTN) or increased abdominal obesity components can have profound effects on the other two systems and contributes to metabolic dysfunction (18, 21). Interestingly, gut dysbiosis and increased intestinal permeability have been observed in individuals with NAFLD and in animal models of NAFLD, suggesting a role for the GI tract in the etiology of NAFLD (22-42). Dysbiosis is also associated with obesity and T2D morbidity and disease course; influencing inflammation, gut permeability, immune function, insulin resistance, and lipid metabolism (43) (44) (45) (46) (47) . Given the reciprocal gut-liver interaction, examining the GI tract in MetS patients could prove beneficial in both interventional strategies and preventative diagnostics.

The purpose of our pilot study was to determine if human subjects with MetS have intestinal inflammation and increased intestinal permeability similar to other metabolic diseases. Additionally, we sought to examine fecal metabolites associated with our clinical phenotype and to further understand metabolic variation as well as interactions between the gut microbiota-host. Our data indicated there is a noticeable difference in fecal lipidomics and some had a strong correlation with both increasing triglyceride and fasting insulin levels. However, there was not a significant difference in intestinal permeability or inflammation between MetS subjects and controls, suggesting metabolic perturbations may arise before gut inflammation and intestinal permeability.

UNM HSC Institutional Review Boards is the Human Research Review Board (HRRC). Under this agreement, UNM HSC assures that all of its activities related to human subjects research will be guided by The Belmont Report, a statement of principles governing the institution in the discharge of its responsibilities for protecting the rights and welfare of human subjects of research conducted at or sponsored by the institution and conducted in accordance with all applicable regulations (e.g., 45 CFR 46, 21 CFR 50, 21 CFR 56, 21 CFR 312, 21 CFR 812). Additionally, the Institution assures that whenever it engages in research to which this Assurances applies, it will comply with the http://www.hhs.gov/ohrp/assurances/assurances/filasurt.html.

Inclusion criteria for MetS participants consisted of individuals between the ages of 30-60 years with at least three of the five risk factors of MetS. The risk factors included i) abdominal obesity: waist circumference ≥ 102 cm in men or ≥ 88 cm in women; ii) elevated triglycerides: ≥ 150 mg/dL, or drug treatment for high triglycerides; iii) low HDL-Cholesterol: < 40 mg/dL in men or < 50 mg/dL in women, or drug treatment for low HDL-Cholesterol; iv) elevated blood pressure: Systolic ≥ 130 mm Hg and/or diastolic ≥ 85 mm Hg, or drug treatment for hypertension; and v) elevated fasting plasma glucose: ≥ 100 mg/dL, or drug treatment for elevated glucose. Inclusion criteria for the control group consisted of individuals aged 30-60 years that did not have MetS. Exclusion criteria for both groups included individuals who have been previously diagnosed with inflammatory bowel disease, diabetes, severe hepatic dysfunction, pregnant females, lactating/breastfeeding individuals, currently on nonsteroidal anti-inflammatory drugs (NSAIDs), protein pump inhibitors, ongoing alcohol or substance abuse using AUDIT questionnaire to determine whether the participant's behaviors were suggestive of alcohol abuse, or inability to render informed consent.

factor-alpha (TNFα) (R&D Systems) were also analyzed (CTSC). Participants' height, weight, waist, waist-to-hip ratio, and body composition via bioelectrical impedance were recorded. Participants were instructed to collect 10 grams of stool for metabolomics (PRECISION™ Stool Collection System, Covidien) and fecal calprotectin. For calprotectin assay, stool was collected in a Calprotectin ELISA Stool Sample Collection Kit and ran on the corresponding ELISA kit (Eagle BioSciences, Inc).

Within two weeks after the initial visit, participants visited the CTSC clinic after fasting overnight and provided a pre-test urine sample. Participants then ingested 50 milliliters of solution containing 5 grams of lactulose and 2 grams of D-mannitol followed immediately by 200 milliliters of water. After 3 hours, participants provided a post-test urine sample. The levels of lactulose, D-mannitol, and lactulose-mannitol ratios were assessed in the urine via ELISA (Megazyme F-FRUGL, Megazyme E-MNHPF) (48) (49) (50) .

The collected 10 grams of stool (PRECISION™ Stool Collection System, Covidien) were sent to NYU Langone Metabolomics Core Resource Laboratory to examine fecal metabolites and lipids. Hybrid metabolomics was performed examining a standard panel of ~150 polar metabolites covering much of central carbon metabolism, and other common metabolites of interest. Separation and identification was carried out with HILIC chromatography and a library of m/z and retention times adapted from the Whitehead Institute (51) , and verified with authentic standards and/or high resolution MS/MS spectral manually curated against the NIST14MS/MS and METLIN (2017) tandem mass spectral libraries (51, 52) .

Global lipidomics analyses were performed to profile changes in polar lipids in a datadependent fashion. Samples were subjected to an LCMS analysis to detect and identify phospholipid molecules and quantify the relative levels of identified lipids. A lipid extraction was carried out on each sample based on published methods (53, 54) . The dried samples were resolubilized in 10 μL of a 4:3:1 mixture . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 26, 2022. ; https://doi.org/10.1101/2022.02.24.22271487 doi: medRxiv preprint (isopropanol:acetonitrile:water) and analyzed by UPLC-MS/MS with a polarity switching method modified (53, 54) . The LC column was a Waters TM CSH-C18 (2.1 x100 mm, 1.7 μm) coupled to a Dionex Ultimate 3000 TM system and the column oven temperature was set to 55 o C for the gradient elution. The flow rate of 0.3 mL/min was used with the following buffers; A) 60:40 acetonitrile:water, 10 mM ammonium formate, 0.1% formic acid and B) 90:10 isopropanol:acetonitrile, 10 mM ammonium formate, 0.1% formic acid. The gradient profile was as follows; 40-43%B (0-1. (nCE) of 10, 35, 80. The minimum AGC target was 5e4 with an intensity threshold of 1e6. All data were acquired in profile mode. The top scoring structure match for each data-dependent spectrum was returned using an in-house script for MSPepSearch_x64 against the LipidBlast tandem mass spectral library of lipids (55) . Putative lipids were sorted from high to low by their reverse dot scores, and duplicate structures were discarded, retaining only the top-scoring MS2 spectrum and the neutral chemical formula, detected m/z, and detected polarity (+ or -) of the putative lipid was recorded.

The resulting lipids were further identified manually by searching the accurate mass data against the LIPID MAPS® Structure Database (LMSD) utilizing the observed m/z (56) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 26, 2022. ; https://doi.org/10.1101/2022.02.24.22271487 doi: medRxiv preprint

Statistical analysis was performed as described in figure legends and plots generated were obtained using Prism software. Plots display median (± minimum and maximum) or mean (± SE). Pearson's Correlation Coefficient were acquired using Prism software.

Fecal metabolomics data were processed as described above and analyzed by NYU Langone Metabolomics Core Resource Laboratory using their in-house analysis pipeline. Cluster analysis was performed using heatmap3 (57) package in R. Raw pvalues < 0.05 were used as a significance threshold for prioritizing hits of interest.

Principle component analysis was conducted in Python using the Scikit-learn, matplotlib, Numpy, and Scipy. (58) (59) (60) (61) . All other data were analyzed using two-tailed unpaired Student's t test (Prism).

In this pilot study, we sought to understand differences in gut health in individuals with metabolic syndrome (MetS) compared to non-metabolic syndrome (control) participants.

Specifically, examining differences in intestinal inflammation, intestinal permeability, and fecal metabolites as an insight between diet-microbiota-host interactions. This pilot study was approved by UNM HSC HRRC (see methods) and participants were recruited to and seen at UNM CTSC clinic in a two-week period. Participants were classified as having MetS or normal based on established criteria described in methods.

The study population consisted of 18 individuals who were seen under fasting conditions. The demographics of the study cohort are found in Table 1 Table 1) .

Bioelectrical impedance analysis further revealed the MetS group had significantly . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 26, 2022. ; https://doi.org/10.1101/2022.02.24.22271487 doi: medRxiv preprint higher fat mass with no difference in lean mass ( Supplementary Fig. 1A Table 2 ). Collectively, our MetS cohort showed significant differences in abdominal obesity, dyslipidemia, and insulin resistance.

Metabolic disorders are frequently associated with low-grade inflammation (65) . The term metabolic inflammation characterizes a low-level of systemic inflammation. As such, several studies have associated these conditions with increased circulating levels of acute phase proteins and cytokines such as C-reactive protein (CRP) and TNFα, respectively. To determine the level of metabolic inflammation occurring in our two groups, we examined serum levels of both TNFα and high-sensitivity C-reactive protein (hsCRP) as proxies for metabolic inflammation (66, 67) . Serum TNFα levels were found to be significantly higher in the MetS group ( Fig. 2A) . HsCRP levels were slightly higher in the MetS group; however, this difference was not significant (Fig. 2B) . Intriguingly, there was a strong positive correlation between increasing TNFα levels and increasing triglyceride levels (r=0.7978; p=0.0177) (Fig. 2D ). Rising TNFα levels also had a strong negative correlation with decreasing HDL cholesterol levels (r= -0.7094; p=0.0488) (Fig.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 26, 2022. ; https://doi.org/10.1101/2022.02.24.22271487 doi: medRxiv preprint 2E). These results are consistent with the previously reported correlation between TNFα levels and dyslipidemia (68, 69) .

More recently, attention has been drawn to the GI tract as a possible etiological factor driving metabolic disorders (21, 45, 65, 70) . In fact, MetS and NAFLD are frequently reported in patients with inflammatory bowel disease (IBD) (71) (72) (73) (74) (75) . Therefore, we examined the level of intestinal inflammation through a fecal calprotectin test. This noninvasive test provides a functional quantitative measure of intestinal inflammation (76) (77) (78) . Interestingly, we saw no difference in fecal calprotectin levels between the control and MetS groups (Fig. 2C ). Further analysis of the GI tract revealed no significant difference in intestinal barrier permeability as the lactulose to mannitol ratio was similar between both groups (Fig. 2F) , as were the overall levels of recovered urine lactulose (Fig. 2G ) and mannitol (Fig. 2H ). This test allows for the quantification of two non-metabolized sugar molecules (i.e., lactulose and mannitol) to permeate the intestinal barrier (79) . Taken together, our data suggests the MetS group has a low-level of systemic inflammation but no observable signs of intestinal inflammation or barrier dysfunction.

Utilizing untargeted lipidomic analyses (53, 54) , we sought to identify lipids associated with our clinical phenotype. Specifically, we analyzed fecal samples from our control and MetS groups to further characterize the GI tract. Figure 3A Table 2 ). Out of these 20 lipids, LMSD predicted they were glycerolipids, glycerophospholipids, sphingolipids, fatty acyls, and polyketides (Fig. 3B ). For brevity, we also show the 30 with the lowest p-values in Supp. Table 3 and Supp. Fig. 2A .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 26, 2022. ; https://doi.org/10.1101/2022.02.24.22271487 doi: medRxiv preprint Among these 30 lipids, LMSD predicted that all were still glycerolipids (n=9), glycerophospholipids (n=18), and sphingolipids (n=3) (Supplementary Table 3 

In this present study, we evaluated intestinal homeostasis in individuals with or without MetS. Interestingly, MetS participants showed no signs of intestinal inflammation or increased intestinal permeability when compared to our control group. Nonetheless, we . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 26, 2022. ; https://doi.org/10.1101/2022.02.24.22271487 doi: medRxiv preprint found major differences in the gut lipidome, specifically, an increase in various types of glycerolipids, glycerophospholipids, sphingolipids, fatty acyls, and polyketides, in our MetS cohort. One fecal lipid that was identified, a diacyl-glycerophosphocholine, was increased in our MetS cohort and showed a strong correlation with several MetS risk factors. Furthermore, we found our MetS cohort had a low-level of circulating TNFα that also correlated with increasing triglyceride and fecal diacyl-glycerophosphocholine levels as well as decreasing "good" HDL cholesterol levels. Taken MetS and NAFLD can both predict similar diseases including T2D, CVD and NASH (81, 82) . In addition, the liver is a shared focal point for both metabolic disorders as glucose and triglycerides are overproduced in the liver. The increase in triglycerides can lead to fat accumulation and is often associated with hepatic insulin resistance (12) .

Unfortunately, both metabolic disorders can go undiagnosed as the individual can appear asymptomatic. Given the role of the liver in these two metabolic diseases, liver enzymes (e.g., ALT, AST, ALT:AST) could provide clues to disease progression.

However, we observed no differences in these liver enzymes between our study groups (Supplementary Table 2 ). Liver enzymes are also often normal in NAFLD patients and therefore not consistent diagnostic markers (12) . The gold standard of NAFLD diagnosis relies on liver biopsy. Liver biopsy is an invasive procedure with many absolute contraindications (coagulopathies, recent NSAID use, inability to identify an appropriate biopsy site) and relative contraindications (morbid obesity, infection, ascites). A liver biopsy is also handicapped by only being able to capture pathology in a specific moment in time. NAFLD is a chronic inflammatory disease. Like many chronic inflammatory disorders, NAFLD can have a dynamic relapsing-remitting pattern (65) .

Over a short period of time NAFLD can oscillate between steatosis and steatohepatitis (65) . Fibrosis can flare and spontaneously regress (65) . Additionally, a liver biopsy cannot accurately assess a fluctuating disease process. It is therefore not appropriate to do liver biopsies on all patients with suspected NAFLD or MetS, even if a biopsy is . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 26, 2022. ; https://doi.org/10.1101/2022.02.24.22271487 doi: medRxiv preprint medically feasible (83) . Safer, faster, and more accessible testing is needed.

Metabolomics may offer a non-invasive, accurate method of screening for both MetS and NAFLD. Metabolomics can analyze and quantify metabolites and lipids linked to metabolic pathways and changes could offer insight into clinical phenotypes.

Mining biofluids such as plasma, serum, urine and even stool can help identify biomarkers for diseases. Unlike other biofluids, stool gives a comprehensive look into the GI tract as it contains microorganisms, microbial by-products, nutrients such as fibers and lipids, and inflammatory molecules. Thus, stool samples can provide molecular clues into GI health. For instance, bacterial fermentation of dietary fiber can generate metabolites such as short chain fatty acids (SCFAs) such butyrate, propionate and acetate that in turn modulate microbiota composition, intestinal epithelial and immune cell function, and lipid metabolism (84) (85) (86) (87) (88) (89) (90) (91) . When the production of SCFAs is decreased from dysbiosis, it can subsequently derail barrier and immune function as well as lipid metabolic pathways. Our metabolomic analyses of stool samples revealed major alterations in the gut lipidome in individuals with MetS. We observed increases in glycerophospholipids like glycerophosphocholines as well as ceramides, a type of sphingolipids. Both glycerophosphocholines and ceramides are increased in the serum of NAFLD and NASH patients (92) (93) (94) . They are also strongly associated with CVD and T2D (95) (96) (97) (98) (99) . A reduction in ceramides can improve hepatic steatosis and insulin sensitivity (100, 101) . Interestingly, gut microbiota produced sphingolipids can be taken up by the intestine (102) and can enter into host metabolic pathways increasing hepatic ceramide levels (103) . In addition to changes in fecal lipids, our MetS cohort also showed an increase in orotic acid, an intermediate of pyrimidine nucleotide biosynthesis, in stool samples. Similar to the lipids described above, orotic acid has also been linked to metabolic risk factors like hypertension (104) and can induce NAFLD in a various rodent models (105, 106) . Carnosine, which was decreased in our MetS group, has proven beneficial in reducing abdominal obesity, blood pressure and glucose in humans and animal models (107) (108) (109) (110) (111) . Overall, our observation of differential lipids and metabolites that associated with clinical phenotypes suggest stool samples could prove beneficial as a diagnostic or preventative biofluid for metabolic disorders.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 26, 2022. ;

Our goal in this pilot study was to examine GI health in individuals with MetS. This cohort showed no signs of intestinal inflammation or increase in intestinal permeability.

Animal models utilizing high-fat diets (plus glucose) to induce obesity, metabolic endotoxemia, and insulin resistances show alterations in the gut microbiota (18, 21). In addition, these models have been instrumental in showing high-fat diets also cause an increase in intestinal permeability and inflammation (45, [112] [113] [114] [115] . In human subjects, intestinal inflammation has been observed in more advanced liver diseases like cirrhosis and HCC (116, 117) . IBD patients also can develop MetS and NAFLD while NAFLD and NASH patients have an increased risk in developing CRC (71) (72) (73) (74) (75) (118) (119) (120) .

Targeting the GI tract with probiotics in NAFLD and NASH patients has proved beneficial in reducing liver enzymes, hepatic inflammation, hepatic steatosis, and hepatic fibrosis further supporting a role for the GI tract (121) (122) (123) (124) (125) (126) (127) (128) (129) (130) . Nevertheless, these studies still do not completely explain the cause of gut dysbiosis and decreased barrier function, the increased risk of IBD and CRC in NAFLD patients or how the probiotics are working. Thus, there is a critical gap in knowledge regarding how the GI tract, possibly through host-microbiota metabolic interaction, is involved in metabolic diseases. We posit our MetS cohort showed no signs of intestinal dysfunction because changes in host-microbiota metabolism precedes inflammation (131) . Future endeavors to characterize gut metabolism could provide insight into the etiology of metabolic disorders like MetS and NAFLD.

The datasets generated and analyzed during this study are not publicly available because of institutional review board restrictions, but data acquisition is described in methods. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

The Global Epidemic of the Metabolic Syndrome

A Sustainable Approach to the Metabolic Syndrome in Children and Its Economic Burden

Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model

The metabolic syndrome

Impact of Metabolic Syndrome and It's Components on Prognosis in Patients With Cardiovascular Diseases: A Meta-Analysis

The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis

Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness

Diagnosis of non-alcoholic fatty liver disease (NAFLD)

Metabolic syndrome and hepatocellular carcinoma risk

Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men

Liver fat in the metabolic syndrome

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low-grade inflammation and the development of obesity and diabetes

Standardising the lactulose mannitol test of gut permeability to minimise error and promote comparability

Lactulose-mannitol intestinal permeability test: a useful screening test for adult coeliac disease

Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn's disease

Absolute Quantification of Matrix Metabolites Reveals the Dynamics of Mitochondrial Metabolism

METLIN: a metabolite mass spectral database

Metabolic phenotyping of atherosclerotic plaques reveals latent associations between free cholesterol and ceramide metabolism in atherogenesis

Untargeted UPLC-MS profiling pipeline to expand tissue metabolome coverage: application to cardiovascular disease

LipidBlast in silico tandem mass spectrometry database for lipid identification

Template-based combinatorial enumeration of virtual compound libraries for lipids

Advanced heat map and clustering analysis using heatmap3

SciPy 1.0: fundamental algorithms for scientific computing in Python

Array programming with NumPy

Matplotlib: A 2D graphics environment

Scikit-learn: Machine Learning in Python

Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes

QUICKI is a useful and accurate index of insulin sensitivity

Validity of HOMA-IR as index of insulin resistance in obesity

The intestinal microbiota fuelling metabolic inflammation

High-sensitivity C-reactive protein: clinical importance

The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk

Tumor necrosis factor-alpha is a marker of familial combined hyperlipidemia, independently of metabolic syndrome

Tumor necrosis factor, cytokines, and the hyperlipidemia of infection

Immunologic impact of the intestine in metabolic disease

Risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel disease

Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history

Common links between metabolic syndrome and inflammatory bowel disease: Current overview and future perspectives

Metabolic Syndrome in Inflammatory Bowel Disease: Association with Genetic Markers of Obesity and Inflammation

Connecting the Dots Between Inflammatory Bowel Disease and Metabolic Syndrome: A Focus on Gut-Derived Metabolites

The Use of Fecal Calprotectin in Inflammatory Bowel Disease

Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease

Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease

For the assessment of intestinal permeability, size matters

HMDB 5.0: the Human Metabolome Database for 2022

The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

American Gastroenterological A, American Association for the Study of Liver D, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association

The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism

Contribution of Gut Bacteria to Lipid Levels: Another Metabolic Role for Microbes?

Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability

The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis

Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity

Microbiotaderived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis

A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease

Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function

Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity

Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial

Hepatic ceramides dissociate steatosis and insulin resistance in patients with nonalcoholic fatty liver disease

Glycerophosphocholine Metabolites and Cardiovascular Disease Risk Factors in Adolescents: A Cohort Study

Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance

Circulating ceramides as biomarkers of cardiovascular disease: Evidence from phenotypic and genomic studies

Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol

Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis

Targeting a ceramide double bond improves insulin resistance and hepatic steatosis

Physiological functions and clinical implications of sphingolipids in the gut

Sphingolipids produced by gut bacteria enter host metabolic pathways impacting ceramide levels

Orotic acid induces hypertension associated with impaired endothelial nitric oxide synthesis

Fatty liver induction by orotic acid

Effects of Orotic Acid-Induced Non-Alcoholic Fatty Liver on the Pharmacokinetics of Metoprolol and its Metabolites in Rats

The effects of l-Carnosine on development of metabolic syndrome in rats

Role of Lcarnosine in the control of blood glucose, blood pressure, thermogenesis, and lipolysis by autonomic nerves in rats: involvement of the circadian clock and histamine

A carnosine analog mitigates metabolic disorders of obesity by reducing carbonyl stress

Effect of carnosine supplementation on the plasma lipidome in overweight and obese adults: a pilot randomised controlled trial

Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation

Long-Term Overconsumption of Fat and Sugar Causes a Partially Reversible Pre-inflammatory Bowel Disease State

High Fat Diets Induce Colonic Epithelial Cell Stress and Inflammation that is Reversed by IL-22

Glucose but Not Fructose Alters the Intestinal Paracellular Permeability in Association With Gut Inflammation and Dysbiosis in Mice

Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection

Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease

Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis

Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study

Site-specific risk of colorectal neoplasms in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis

Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm

Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia

Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease

Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis

Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis

Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis

Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease

Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents

Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis

Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease

Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis

Colonocyte metabolism shapes the gut microbiota